GlassScriptPhysician profile
Edward L White
NPI 1144294992
$3,570.27
in general payments reported to CMS, 2019-2025
26 companies · $58.06 in 2025
The $58.06 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $810 · 2020: $662 · 2021: $840 · 2022: $598 · 2023: $436 · 2024: $167 · 2025: $58.06.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $661.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $660.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $680.99 | 2019-2023 | Repatha, Otezla |
| Glaxosmithkline, LLC. | $608.63 | 2019-2024 | Trelegy Ellipta, Shingrix, Arexvy |
| Novo Nordisk INC | $432.19 | 2019-2022 | |
| Sanofi-Aventis U.S. LLC | $282.97 | 2019-2022 | |
| Astellas Pharma US INC | $269.99 | 2019-2024 | Veozah |
| Astrazeneca Pharmaceuticals LP | $151.55 | 2019-2024 | Airsupra |
| Amarin Pharma, INC. | $150.95 | 2020-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $149.34 | 2022-2023 | |
| Pfizer INC. | $148.83 | 2019-2025 | |
| Abbott Laboratories | $103.69 | 2021-2024 | Freestyle Libre |
| Sunovion Pharmaceuticals INC. | $96.98 | 2020-2022 | |
| Mylan Specialty L.P. | $64.64 | 2019-2022 | |
| Lilly USA, LLC | $52.17 | 2020-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $48.05 | 2021 | |
| Boston Scientific Corporation | $47.66 | 2023 | Wavewriter Alpha Prime 16 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axonics, INC. | $44.27 | 2020-2023 | Axonics |
| Novartis Pharmaceuticals Corporation | $39.85 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $34.98 | 2021-2023 | Austedo Xr |
| Janssen Pharmaceuticals, INC | $28.20 | 2020-2022 | |
| Regeneron Healthcare Solutions, INC. | $27.93 | 2025 | Dupixent |
| E.R. Squibb & Sons, L.L.C. | $25.90 | 2022-2023 | Eliquis |
| Merck Sharp & Dohme LLC | $24.12 | 2019 | |
| Nestle Healthcare Nutrition INC. | $16.71 | 2020 | |
| Genentech USA, INC. | $15.17 | 2019 | |
| Sumitomo Pharma America, INC. | $12.44 | 2023 | Gemtesa |
| Esperion Therapeutics, INC. | $12.07 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Edward White listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.